Haifeng C. Xu, Jun Huang, Aleksandra A. Pandyra, Piyush Pandey, Ruifeng Wang, Zeli Zhang, Yuan Zhuang, Christoph G.W. Gertzen, Carsten Münk, Diran Herebian, Arndt Borkhardt, Mike Recher, Holger Gohlke, Irene Esposito, Martin Oberbarnscheidt, Dieter Häussinger, Karl S. Lang, Philipp A.
13 February 2022
13 February 2022
13 February 2022
Marlyn J. Mayo – 12 February 2022 – Treatment of primary biliary cholangitis (PBC) with ursodeoxycholic acid (UDCA) is not always sufficient to prevent progression to hepatic decompensation and/or need for liver transplant. Adjuvant therapy with obeticholic acid may provide additional biochemical improvements in some patients, but it is not well‐tolerated by patients with significant itch or advanced cirrhosis. Thus, new and creative approaches to treating patients with PBC are important to identify.
Gautam Kok, Monique M. A. Verstegen, Roderick H. J. Houwen, Edward E. S. Nieuwenhuis, Herold J. Metselaar, Wojciech G. Polak, Luc J. W. Laan, Eric Spierings, Caroline M. den Hoed, Sabine A. Fuchs – 12 February 2022 – For liver transplantations, human leukocyte antigen (HLA) matching is not routinely performed because observed effects have been inconsistent. Nevertheless, long‐term liver transplantation outcomes remain suboptimal.
Lintao Song, Luyao Wang, Yushu Hou, Jie Zhou, Chuchu Chen, Xianxi Ye, Wenliya Dong, Huan Gao, Yi Liu, Guanting Qiao, Tongtong Pan, Qiong Chen, Yu Cao, Fengjiao Hu, Zhiheng Rao, Yajing Chen, Yu Han, Minghua Zheng, Yongde Luo, Xiaokun Li, Yongping Chen, Zhifeng Huang – 11 February 2022
Václav Šmíd, Karel Dvořák, Petr Šedivý, Vít Kosek, Martin Leníček, Monika Dezortová, Jana Hajšlová, Milan Hájek, Libor Vítek, Kamila Bechyňská, Radan Brůha – 10 February 2022 – Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease. n‐3 polyunsaturated fatty acids (n‐3‐PUFAs) have been reported to ameliorate the progression of NAFLD in experimental studies; however, clinical trials have yielded contradictory results.
Asher Shafrir, Johnny Amer, David Hakimian, Yael Milgrom, Muhammad Massarwa, Wadi Hazou, Ashraf Imam, Abed Khalaileh, Rifaat Safadi – 10 February 2022 – The Pfizer‐BioNTech coronavirus disease 2019 (COVID‐19) vaccine has been offered to nonallergic ≥16‐year‐old Israeli adults since December 19, 2020. Data regarding factors associated with vaccine ineffectiveness are limited. The aim of this study is to assess the impact of hepatic fibrosis on the efficacy of the BioNTech vaccine.
Grazia Pennisi, Rosaria Maria Pipitone, Marco Enea, Antonio De Vincentis, Salvatore Battaglia, Vito Di Marco, Vincenzo Di Martino, Federica Spatola, Federica Tavaglione, Umberto Vespasiani‐Gentilucci, Rossella Zito, Stefano Romeo, Calogero Cammà, Antonio Craxì, Stefania Grimaudo, Salvatore Petta – 10 February 2022 – Nonalcoholic fatty liver disease (NAFLD) is an emerging cause of liver‐related events (LREs). Here, we have assessed the ability of a composite score based on clinical features, metabolic comorbidities, and genetic variants to predict LREs.